Trial Profile
A Phase IB Dose Exploration Trial With MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects With Selected Advanced Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Birabresib (Primary)
- Indications Advanced breast cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme Corp.
- 11 Apr 2019 This trial has been completed in France, according to European Clinical Trials Database.
- 04 Aug 2017 This trial has been completed in Belgium (end date: 26 Apr 2017).
- 23 May 2017 Status changed from completed to discontinued.